IDEAYA Biosciences, Inc. (IDYA) shareholders
Close on Nov 17, 2026Market cap $2.64BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (14.96%) | 12,635,652 | 14.96% | 13G (passive) amendment | Nov 12, 2024 |
| Janus Henderson Group PLC | 7,265,253 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 7,130,507 | 8.10% | 13G (passive) amendment | Mar 31, 2025 |
| Capital Research Global Investors | 5,279,675 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (5.20%), Baker Bros. Advisors (GP) LLC (5.20%) and 1 more | 5,010,030 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 4,834,771 | 5.08% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IDYA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 14,109,431 | 14.62% | $525.86M | +937,328 | 0.02% |
| BlackRock, Inc. | 8,893,260 | 9.22% | $331.45M | +451,127 | 0.00% |
| Jupiter Topco LLC | 8,579,881 | 8.89% | $319.73M | New | 0.13% |
| Capital Research Global Investors | 5,344,701 | 5.54% | $199.20M | +181,158 | 0.03% |
| Baker Bros. Advisors LP | 5,010,030 | 5.19% | $186.72M | +1,063,515 | 0.94% |
| State Street Corp | 4,548,911 | 4.71% | $169.54M | +767,744 | 0.01% |
| Vanguard Capital Management LLC | 4,132,646 | 4.28% | $154.02M | +400,224 | 0.00% |
| Logos Global Management LP | 3,000,000 | 3.11% | $111.81M | −450,000 | 4.81% |
| Adage Capital Partners Gp, L.L.C. | 2,715,391 | 2.81% | $101.20M | −108,109 | 0.14% |
| Deerfield Management Company, L.P. (Series C) | 2,714,503 | 2.81% | $101.17M | +1,184,495 | 1.06% |
| Geode Capital Management, LLC | 2,425,602 | 2.51% | $90.42M | −75,122 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,207,451 | 2.29% | $82.27M | +891,582 | 0.01% |
| Morgan Stanley | 1,931,491 | 2.00% | $71.99M | +71,038 | 0.00% |
| Dimensional Fund Advisors LP | 1,661,281 | 1.72% | $61.91M | +327,803 | 0.01% |
| Alliancebernstein L.P. | 1,627,521 | 1.69% | $54.23M | +1,526,735 | 0.02% |
| Fiera Capital Corp | 1,445,885 | 1.50% | $53.89M | −1,081,191 | 0.20% |
| Federated Hermes, Inc. | 1,431,630 | 1.48% | $53.36M | −1,555,477 | 0.08% |
| GSK plc | 1,333,333 | 1.38% | $49.69M | – | 8.25% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,269,889 | 1.32% | $47.33M | +168,744 | 0.05% |
| Goldman Sachs Group Inc | 1,231,614 | 1.28% | $45.90M | −424,003 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 284 | 102M | 100.0% | 66 / 92 | 89 / 33 | 23M | 8M |
| Q1 2026 | 254 | 95M | 98.1% | 46 / 86 | 76 / 32 | 11M | 7M |
| Q4 2025 | 246 | 96M | 99.4% | 55 / 83 | 74 / 27 | 11M | 9M |
| Q3 2025 | 224 | 94M | 97.7% | 45 / 82 | 68 / 22 | 9M | 12M |
| Q2 2025 | 204 | 97M | 100.0% | 31 / 77 | 75 / 31 | 15M | 12M |
| Q1 2025 | 207 | 94M | 97.3% | 27 / 103 | 49 / 25 | 10M | 7M |
| Q4 2024 | 206 | 92M | 95.3% | 34 / 94 | 56 / 35 | 11M | 11M |
| Q3 2024 | 209 | 92M | 95.3% | 35 / 106 | 47 / 24 | 23M | 8M |
| Q2 2024 | 199 | 85M | 87.6% | 29 / 90 | 62 / 32 | 10M | 6M |
| Q1 2024 | 204 | 81M | 83.6% | 59 / 78 | 53 / 12 | 19M | 7M |
| Q4 2023 | 157 | 68M | 70.3% | 30 / 75 | 39 / 14 | 19M | 8M |
| Q3 2023 | 144 | 60M | 61.9% | 18 / 63 | 41 / 12 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
248 funds held IDYA in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IDYA | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 5,202,950 | 5.39% | $193.91M | 0.20% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 4,237,561 | 4.39% | $124.88M | 0.13% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,964,950 | 3.07% | $110.50M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,314,401 | 2.40% | $86.26M | 0.80% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,152,842 | 2.23% | $80.24M | 0.10% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,240,259 | 1.29% | $36.55M | 0.13% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 1,082,838 | 1.12% | $31.91M | 0.13% | May 31, 2026 |
| Janus Henderson Triton Fund | 1,074,589 | 1.11% | $40.05M | 0.68% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,041,974 | 1.08% | $38.83M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 916,934 | 0.95% | $32.55M | 0.10% | Jul 31, 2026 |
| Federated Hermes Kaufmann Fund | 878,705 | 0.91% | $31.19M | 0.63% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 757,659 | 0.79% | $28.24M | 0.49% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 726,971 | 0.75% | $27.09M | 0.23% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 704,874 | 0.73% | $26.27M | 0.18% | Jun 30, 2026 |
| Janus Henderson Venture Fund | 672,162 | 0.70% | $25.05M | 0.69% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yujiro S. Hata | President and CEO, Director | 690,695 | 0.72% | Oct 8, 2026 |
| Briseno Andres Ruiz | Chief Accounting Officer | 36,016 | 0.04% | Jul 9, 2026 |
| Theodora Ross | Chief Development Officer | – | – | Jun 5, 2026 |
| Joshua Bleharski | Chief Financial Officer | – | – | Feb 2, 2026 |
| Michael Anthony White | Chief Scientific Officer | 0 | – | Feb 2, 2026 |
| Darrin Beaupre | Chief Medical Officer | – | – | Feb 2, 2026 |
| Douglas B. Snyder | SVP, General Counsel | 2,080 | 0.00% | Feb 2, 2026 |
| Stuart Dorman | Chief Commercial Officer | – | – | Feb 2, 2026 |
| Wendy L. Yarno | Director | – | – | Jun 18, 2026 |
| Catherine J. Mackey | Director | – | – | Jun 18, 2026 |
| Scott W. Morrison | Director | – | – | Jun 18, 2026 |
| Malcolm Garret Hampton | Director | – | – | Jun 18, 2026 |
| Terry J. Rosen | Director | 16,346 | 0.02% | Jun 18, 2026 |
| Jeffrey Stein | Director | 57,644 | 0.06% | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yujiro S. Hata President and CEO, Director | Oct 6, 2026 | Sale(10b5-1 plan) | −800 | $38.26 | $30.61K | 690,695 |
| Yujiro S. Hata President and CEO, Director | Oct 6, 2026 | Sale(10b5-1 plan) | −25,538 | $37.39 | $954.79K | 691,495 |
| Yujiro S. Hata President and CEO, Director | Oct 6, 2026 | Option exercise | +26,338 | $4.31 | $113.52K | 717,033 |
| Briseno Andres Ruiz Chief Accounting Officer | Jul 7, 2026 | Option exercise | +9,550 | $12.86 | $122.81K | 36,016 |
| Briseno Andres Ruiz Chief Accounting Officer | Jul 7, 2026 | Sale(10b5-1 plan) | −9,550 | $40.01 | $382.10K | 26,466 |
| Jeffrey Stein Director | Mar 2, 2026 | Buy | +50,000 | $32.96 | $1.65M | 54,281 |
| Douglas B. Snyder SVP, General Counsel | Nov 28, 2025 | Award | +1,041 | $16.91 | $17.60K | 2,080 |
| Briseno Andres Ruiz See Remarks | Nov 28, 2025 | Award | +1,253 | $16.91 | $21.19K | 26,466 |
| Douglas B. Snyder SVP, General Counsel | May 30, 2025 | Award | +1,039 | $16.91 | $17.57K | 1,039 |
| Yujiro S. Hata President and CEO, Director | Feb 18, 2025 | Option exercise | +12,808 | $19.52 | $250.01K | 690,695 |
| Briseno Andres Ruiz See Remarks | Nov 29, 2024 | Award | +682 | $23.26 | $15.86K | 25,213 |
| Jason Throne Chief Legal Officer | Jun 27, 2024 | Option exercise | +6,424 | $13.34 | $85.70K | 16,424 |
| Jason Throne Chief Legal Officer | Jun 27, 2024 | Option exercise | +47,060 | $7.01 | $329.89K | 63,484 |
| Michael Anthony White Chief Scientific Officer | May 29, 2024 | Sale(10b5-1 plan) | −851 | $36.78 | $31.30K | 0 |
| Michael Anthony White Chief Scientific Officer | May 29, 2024 | Option exercise | +28,500 | $12.86 | $366.51K | 28,500 |
| Michael Anthony White Chief Scientific Officer | May 29, 2024 | Sale(10b5-1 plan) | −27,649 | $36.23 | $1.00M | 851 |
| Yujiro S. Hata President and CEO, Director | May 16, 2024 | Sale(10b5-1 plan) | −30,084 | $41.73 | $1.26M | 682,236 |
| Yujiro S. Hata President and CEO, Director | May 16, 2024 | Option exercise | +34,433 | $4.31 | $148.41K | 712,320 |
| Yujiro S. Hata President and CEO, Director | May 16, 2024 | Sale(10b5-1 plan) | −4,349 | $42.37 | $184.27K | 677,887 |
| Yujiro S. Hata President and CEO, Director | May 15, 2024 | Option exercise | +83,856 | $4.31 | $361.42K | 761,743 |
| Yujiro S. Hata President and CEO, Director | May 15, 2024 | Sale(10b5-1 plan) | −503 | $44.12 | $22.19K | 677,887 |
| Yujiro S. Hata President and CEO, Director | May 15, 2024 | Sale(10b5-1 plan) | −29,761 | $43.48 | $1.29M | 678,390 |
| Yujiro S. Hata President and CEO, Director | May 15, 2024 | Sale(10b5-1 plan) | −53,592 | $42.57 | $2.28M | 708,151 |
| Yujiro S. Hata President and CEO, Director | May 14, 2024 | Sale(10b5-1 plan) | −2,303 | $41.84 | $96.36K | 677,887 |
| Yujiro S. Hata President and CEO, Director | May 14, 2024 | Sale(10b5-1 plan) | −54,408 | $41.60 | $2.26M | 680,190 |
| Yujiro S. Hata President and CEO, Director | May 14, 2024 | Option exercise | +56,711 | $4.31 | $244.42K | 734,598 |
| Briseno Andres Ruiz See Remarks | Feb 9, 2024 | Sale(10b5-1 plan) | −2,000 | $46.02 | $92.04K | 24,531 |
| Yujiro S. Hata President and CEO, Director | Feb 9, 2024 | Sale(10b5-1 plan) | −23,557 | $45.54 | $1.07M | 677,887 |
| Yujiro S. Hata President and CEO, Director | Feb 9, 2024 | Option exercise | +23,557 | $4.31 | $101.53K | 701,444 |
| Yujiro S. Hata President and CEO, Director | Feb 8, 2024 | Sale(10b5-1 plan) | −75,815 | $45.15 | $3.42M | 677,887 |
| Yujiro S. Hata President and CEO, Director | Feb 8, 2024 | Option exercise | +75,815 | $4.31 | $326.76K | 753,702 |
| Yujiro S. Hata President and CEO, Director | Feb 1, 2024 | Sale(10b5-1 plan) | −624 | $45.00 | $28.08K | 677,891 |
| Yujiro S. Hata President and CEO, Director | Feb 1, 2024 | Sale(10b5-1 plan) | −4 | $45.01 | $180 | 677,887 |
| Yujiro S. Hata President and CEO, Director | Feb 1, 2024 | Option exercise | +628 | $4.31 | $2.71K | 678,515 |
| Briseno Andres Ruiz See Remarks | Jan 22, 2024 | Sale(10b5-1 plan) | −2,000 | $42.03 | $84.06K | 26,531 |
| Yujiro S. Hata President and CEO, Director | Jan 16, 2024 | Sale(10b5-1 plan) | −62,739 | $40.17 | $2.52M | 677,887 |
| Yujiro S. Hata President and CEO, Director | Jan 16, 2024 | Option exercise | +62,739 | $4.31 | $270.41K | 740,626 |
| Yujiro S. Hata President and CEO, Director | Jan 12, 2024 | Option exercise | +12,261 | $4.31 | $52.84K | 690,148 |
| Yujiro S. Hata President and CEO, Director | Jan 12, 2024 | Sale(10b5-1 plan) | −12,261 | $40.04 | $490.93K | 677,887 |
| Briseno Andres Ruiz See Remarks | Jan 12, 2024 | Sale(10b5-1 plan) | −2,000 | $38.01 | $76.02K | 28,531 |
| Jason Throne Chief Legal Officer | Dec 18, 2023 | Option exercise | +10,000 | $7.01 | $70.10K | 10,000 |
| Yujiro S. Hata President and CEO, Director | Dec 15, 2023 | Sale(10b5-1 plan) | −75,000 | $35.03 | $2.63M | 677,887 |
| Yujiro S. Hata President and CEO, Director | Dec 15, 2023 | Option exercise | +75,000 | $4.31 | $323.25K | 752,887 |
| Jason Throne Chief Legal Officer | Dec 15, 2023 | Option exercise | +10,000 | $13.34 | $133.40K | 10,000 |
| Jason Throne Chief Legal Officer | Dec 15, 2023 | Sale(10b5-1 plan) | −10,000 | $35.04 | $350.40K | 0 |
| Briseno Andres Ruiz See Remarks | Dec 14, 2023 | Sale(10b5-1 plan) | −1,672 | $34.00 | $56.85K | 30,859 |
| Briseno Andres Ruiz See Remarks | Dec 14, 2023 | Sale(10b5-1 plan) | −328 | $34.01 | $11.16K | 30,531 |
| Jason Throne Chief Legal Officer | Nov 3, 2023 | Sale(10b5-1 plan) | −5,163 | $30.09 | $155.35K | 0 |
| Jason Throne Chief Legal Officer | Nov 3, 2023 | Option exercise | +5,163 | $12.86 | $66.40K | 5,163 |
| Jason Throne Chief Legal Officer | Sep 12, 2023 | Sale(10b5-1 plan) | −500 | $30.00 | $15.00K | 500 |
| Jason Throne Chief Legal Officer | Sep 12, 2023 | Sale(10b5-1 plan) | −500 | $30.01 | $15.01K | 0 |
| Jason Throne Chief Legal Officer | Sep 12, 2023 | Option exercise | +1,000 | $12.86 | $12.86K | 1,000 |
| Jason Throne Chief Legal Officer | Sep 5, 2023 | Option exercise | +1,737 | $12.86 | $22.34K | 1,737 |
| Jason Throne Chief Legal Officer | Sep 5, 2023 | Sale(10b5-1 plan) | −1,737 | $30.03 | $52.16K | 0 |
| Jason Throne Chief Legal Officer | Sep 1, 2023 | Option exercise | +2,100 | $12.86 | $27.01K | 2,100 |
| Jason Throne Chief Legal Officer | Sep 1, 2023 | Sale(10b5-1 plan) | −2,100 | $30.03 | $63.06K | 0 |
| Briseno Andres Ruiz See Remarks | Sep 1, 2023 | Sale(10b5-1 plan) | −2,000 | $30.01 | $60.02K | 32,531 |
| Paul A. Stone Chief Financial Officer | Aug 29, 2023 | Sale(10b5-1 plan) | −5,000 | $28.87 | $144.35K | 9,303 |
| Paul A. Stone Chief Financial Officer | Aug 21, 2023 | Sale(10b5-1 plan) | −978 | $26.40 | $25.82K | 14,303 |
| Paul A. Stone Chief Financial Officer | Aug 18, 2023 | Sale(10b5-1 plan) | −3,822 | $26.38 | $100.82K | 15,281 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of IDEAYA Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 86,800 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Yujiro S. Hata CEO | Oct 6, 2026 | 230,316 | $8.80M | Oct 6, 2026 | Stock Option Exercise |
| Briseno Andres Ruiz Senior VP | Jul 7, 2026 | 9,550 | $382.13K | Jul 7, 2026 | Stock Option Exercise |
| Jason Throne Former Officer | Aug 26, 2024 | 75,000 | $3.02M | Aug 26, 2024 | Stock Option Exercise |
| Michael Anthony White Officer | May 29, 2024 | 28,500 | $1.05M | May 29, 2024 | Stock Option Exercise |
| Yujiro S. Hata CEO | May 14, 2024 | 175,000 | $7.24M | May 14, 2024 | Stock Option Exercise |
| Briseno Andres Ruiz Senior VP | Feb 9, 2024 | 14,867 | $677.94K | Feb 9, 2024 | Stock Option Exercise |
| Yujiro S. Hata CEO | Feb 1, 2024 | 100,000 | $4.50M | Feb 1, 2024 | Stock Option Exercise |
| Yujiro S. Hata CEO | Jan 12, 2024 | 75,000 | $3.00M | Jan 12, 2024 | Stock Option Exercise |
| Briseno Andres Ruiz Senior VP | Jan 12, 2024 | 4,000 | $149.48K | Jan 12, 2024 | Stock Option Exercise |
| Paul Stone Officer | Dec 27, 2023 | 55,680 | $1.95M | Dec 27, 2023 | Stock Option Exercise |
| Jason Throne Officer | Dec 15, 2023 | 10,000 | $350.37K | Dec 15, 2023 | Stock Option Exercise |
| Yujiro S. Hata CEO | Dec 15, 2023 | 75,000 | $2.63M | Dec 15, 2023 | Stock Option Exercise |
| Briseno Andres Ruiz Senior VP | Dec 14, 2023 | 2,000 | $68.02K | Dec 14, 2023 | Stock Option Exercise |
| Paul Stone Officer | Dec 11, 2023 | 44,875 | $1.41M | Dec 11, 2023 | Stock Option Exercise |
| Paul Stone Officer | Dec 4, 2023 | 42,964 | $1.39M | Dec 4, 2023 | Stock Option Exercise |
See a number that looks wrong?